SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
JNJ Analysis & Videos »
JNJ: Bull or Bear?
FDA, Clinical Trial Updates: Heart Stents, Cholesterol in the News
JNJ
|
|
|
+0.20%
in
44 days
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
FDA Calendar Updates: ACUS, APPY, APPA, ALKS, JNJ
JNJ
|
|
|
-0.32%
in
2 days
(closed on 05/20/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA fo...
|
Johnson & Johnson (JNJ): 'A buy for any portfolio'
JNJ
+9.70%
in
65 days
Filed under: International markets, Newsletters, Johnson and Johnson (JNJ), DJIA, Stocks to Buy "Health-care stocks have been volatile of late, as the prospects for significant healthcare reform are impacting the group," notes Chuck Carlson. In The DRIP Investor, he explains, "Johnson & Johnson (NYSE: JNJ) has not been immune to the weakness. And while these shares could remain under pressure in the short run, the company's prospects are significantly brighter than the typical health-care stock." <>"First, Johnson & Johnson's diversified business portfolio, which includes pharmaceuticals, medica...
|
FDA, Clinical Trial Updates: Pro-Pharma Looks Promising
JNJ
|
|
|
+9.22%
in
24 days
(closed on 05/18/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Updated Clinical Trial and FDA Decision Calendars
JNJ
|
|
|
-2.12%
in
24 days
(closed on 04/13/09)
Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars. <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and descrip...
|
Updated Clinical Trial and FDA Decision Calendars
JNJ
|
|
|
+4.49%
in
3 days
(closed on 03/20/09)
<> <> Updated Clinical Trial and FDA Calendars
Below is a summary of updates to the www.BioMedReports.co <wbr> </wbr> m database of 243 entries included in the FDA and Clinical Trial Calendars.
http://biomedreports <wbr> </wbr> .com/fda-calendar.ht <wbr> </wbr> ml
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through today. The FDA Calend...
|
Cramer on BloggingStocks: What to buy in the Dow
JNJ
+19.79%
in
116 days
Filed under: Dell (DELL), Hewlett-Packard (HPQ), Wal-Mart (WMT), Coca-Cola (KO), PepsiCo (PEP), Market matters, McDonald's (MCD), AT and T (T), Caterpillar (CAT), Citigroup Inc. (C), Johnson and Johnson (JNJ), Alcoa Inc (AA), Altria Group (MO), Bank of America (BAC), Verizon Communications (VZ), Freep't McMoRan Copper (FCX), DJIA, Stocks to Buy, Cramer on BloggingStocks TheStreet.com's Jim Cramer identifies the eight Dow components that will become too cheap not to buy.
When I arrived ...
|
Cytori Therapeutics: A Natural Play on Cosmetic Medicine
JNJ
|
|
|
+2.31%
in
16 days
(closed on 03/17/09)
The ETF Innovators Global Stem Cell and Regenerative Medicine Index includes 40 companies with market caps less than $1B at the index inception on 2/22/09 and the total market value of the index is down 7.6% at 3,629 from a starting value of 3,928. The index is down 26.3% over the past year on an equal-weight basis, compared to losses of 34.5% for the Healthcare Sector SPDR (XLV), 17.1% for iShares Nasdaq Biotech (IBB), 9.8% for SPDR S&P Biotech (XBI), 26.5% for PowerShares Biotech & Genome (PBE), and 43.4% for the S&P 500 SPDR (SPY). <> In the near-term, President Obama i...
|
Global Q&A: Using both fundamentals and momentum
JNJ
+14.24%
in
126 days
Filed under: International markets, Exxon Mobil (XOM), Johnson and Johnson (JNJ), Chevron Corp (CVX), Unilever ADR (UL), Stocks to Buy  I am the Global Editor at MoneyShow.com and each week I interview an investing expert. This week, I spoke with Cynthia Tusan, president of Strategic Global Advisors -- a woman-owned asset management firm -- who discusses her approach to global investing.<><>Q. Cynthia, your stated strategy is a fundamental, bottom-up approach, focusing on international companies. With that in mind, which are the three most important criteria that you use to determine whether a...
|
FDA Decision Calendar: Pain Drug Delays Likely
JNJ
|
|
|
-15.85%
in
19 days
(closed on 03/01/09)
FDA Decision Calendar: Pain Drug Delays Likely By Mike Havrilla on 2/9/09 ETF Innovators The tables at my website link below include an updated calendar of 86 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions or new submissions for regulatory approval. Click here for a link to my previous calendars. New FDA Decision Calendar Entries: <> 1.) Biogen Idec (BIIB) and Genentech (DNA) have a PDUFA...
|
People Bullish on JNJ
People Bearish on JNJ
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
|
|
|
|
fas831
(-13.70% risk: conservative)
|
|
Johnson & Johnson vs 3M
- I have been waiting and waiting for JNJ to drop but its really dissapointing seeing such a steady stock..on the other hand is 3M who is JNJ's competito
|
More Resources
|
About Johnson & Johnson
- Answers.com
Billions of investment dollars are sitting on the sidelines for fear of entering the market at the wrong time and losing more money after taking a bath last year. However, the market seems to have hit bottom last March and many investors missed the 40% gain from that point to now.
Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models, who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, 
Over the past week I have heard rumors that 
